Compound Profiling CROs

Leading global pharmaceutical and medical device open-access capability and technology platform. WuXi AppTec provides services spanning from discovery through manufacturing across small molecules, biologics, and cell/gene therapies.

Specialty ADME/PK CRO providing in vitro and in vivo drug metabolism and pharmacokinetic studies. Known for comprehensive ADME characterization using human and animal tissues.

Preclinical ADME and pharmacokinetic service provider now part of Pharmaron. Specializes in in vitro and in vivo DMPK, drug transporter studies, and metabolite identification.

San Diego-based preclinical CRO providing in vitro ADME screening, permeability assays, and metabolic stability studies for drug discovery programmes.

Chinese integrated drug discovery and development CRO providing medicinal chemistry, ADME/PK, pharmacology, toxicology, and CMC services from Shanghai operations.

Integrated pharmaceutical R&D service platform offering drug discovery, preclinical, clinical, and commercial manufacturing services to biotech and pharma companies globally.

Drug discovery and development company offering a range of discovery and preclinical services including target validation, hit identification, lead optimization, and ADME/PK.

Specialty CRO providing biochemical and cell-based assay services for drug discovery. Known for kinase profiling, epigenetic screening, and custom assay development.

Translational oncology and metabolic disease CRO providing tumor models (PDX, syngeneic, humanized), oncology pharmacology, and biomarker services for drug discovery.

Eurofins Discovery division providing high-throughput in-vitro pharmacology screening, compound profiling, ADME assays, and bioanalytical services supporting drug discovery from target identification through lead optimization.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

Drug discovery services company providing in vitro pharmacology screening, ADME profiling, and custom assay development for pharmaceutical and biotech companies.

Global CRO/CDMO providing integrated drug discovery and development services including medicinal chemistry, ADME/PK, pharmacology, and process chemistry from US and China operations.

Chinese CRO/CDMO providing integrated drug discovery services including structure-based drug design, medicinal chemistry, ADME/PK studies, and biologics development from Shanghai operations.

Indian integrated research, development, and manufacturing services company serving pharma, biotech, and nutrition companies with discovery chemistry, biology, and manufacturing capabilities.

Indian research services company providing medicinal chemistry, computational chemistry, biology, DMPK, and clinical development services for global pharma and biotech companies.

Integrated drug discovery and development services company providing medicinal chemistry, ADME/DMPK, pharmacology, and clinical research from India, US, and China operations.

Hyderabad-headquartered integrated CRDMO providing CRO and CDMO solutions for small and large molecules to 450+ global pharma and biotech clients with 3,000+ professionals.

Shanghai-headquartered CRO/CDMO offering integrated drug discovery chemistry, biology, and biologics development services including ADC and recombinant protein production.

Specialty preclinical CRO offering bioanalytical chemistry, in vitro ADME screening, physicochemical profiling, and metabolite identification for drug discovery programs.

German preclinical oncology CRO providing patient-derived xenograft models, ex vivo tumor assays, and in vivo efficacy studies for oncology drug development programs.

European ADME and DMPK specialist CRO providing in vitro ADME screening, drug-drug interaction studies, and physicochemical profiling from Macclesfield and Watertown facilities.

Croatian integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, and preclinical development services, now part of Polish CRO Selvita Group.

Polish integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, computational chemistry, and preclinical services with 1,000+ scientists across Europe.

Kansas City-based in vitro ADME and drug metabolism CRO providing hepatocyte-based assays, enzyme induction/inhibition studies, and metabolite identification services.

Hanover, Maryland-based drug screening CRO offering high-throughput receptor binding, enzyme inhibition, and functional cell-based assays for hit-to-lead optimisation programmes.

Verona, Italy-based integrated drug discovery and development centre providing medicinal chemistry, DMPK, safety assessment, and pharmaceutical development under the Evotec umbrella.

Global precision medicine CRO delivering biomarker and bioanalytical services including flow cytometry, histopathology, proteomics, and genomics for clinical trials.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

One of China's earliest chemistry-focused CROs offering integrated drug discovery, DMPK, and pharmaceutical development services globally.

Chinese CRO and CDMO offering integrated preclinical biology, in-vitro pharmacology, and early drug discovery services for domestic and multinational pharma clients.

Kentucky-based preclinical CRO specialising in oncology efficacy studies using proprietary humanised rodent models and patient-derived xenografts for immuno-oncology drug development.

Italy-based CRO specialising in cardiovascular safety pharmacology and cardiac ion channel testing with proprietary automated patch-clamp platforms.

European preclinical CRO in Dijon, France, specializing in oncology, inflammation, and infectious disease drug discovery including targeted radiotherapy programs.

Boulder-based biologic discovery CRO integrating antibody discovery, protein engineering, function-first screening, and early developability assessment for complex biotherapeutics.

Specialty CRO focused on translational oncology services. Champions provides patient-derived xenograft (PDX) tumor models, ex vivo tumor platforms, and oncology pharmacology studies.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.